CoChat
Sign Up
Cited by 42

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer’s disease

Hu, Yan, Cho, Min, Sachdev, Pallavi, Dage, Jeffrey, Hendrix, Suzanne, Hansson, Oskar, Bateman, Randall J., Hampel, Harald·2024·Med
DOI 10.1016/j.medj.2024.08.004
Open this paper in CoChat — free account

Abstract

Clinical management and therapeutics development for Alzheimer's disease (AD) have entered a new era, with recent approvals of monoclonal antibody therapies targeting the underlying pathophysiology of the disease and modifying its trajectory. Imaging and fluid biomarkers are becoming increasingly important in the clinical development of AD therapeutics. This review focuses on the evidence of fluid biomarkers from recent amyloid-β-targeting clinical trials, summarizing biomarker data across 12 trials. It further proposes a simple framework to put biomarker guidance in the context of amyloid-pathway-targeted disease modification, delineates factors that impact biomarker data in clinical trials, and highlights knowledge gaps and future directions. Increased knowledge and data on biomarkers in the context of disease progression and disease modification will help to better design future AD trials and guide the clinical management of patients on AD-modifying therapies, bringing us closer to the implementation of precision medicine in AD.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.medj.2024.08.004

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 75

  1. Ostrowitzki, 2017, A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease, Alzheimer's Res. Ther., 9, 95, 10.1186/s13195-017-0318-y · DOI · Paper page
  2. Rissman, 2024, Plasma Abeta42/Abeta40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease, Alzheimers Dement., 20, 1214, 10.1002/alz.13542 · DOI · Paper page
  3. Hansson, 2023, Blood biomarkers for Alzheimer's disease in clinical practice and trials, Nat. Aging, 3, 506, 10.1038/s43587-023-00403-3 · DOI · Paper page
  4. Aisen, 2013, Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease, Nat. Rev. Drug Discov., 12, 324, 10.1038/nrd3842-c1 · DOI
  5. Hampel, 2011, Biomarkers for Alzheimer's disease therapeutic trials, Prog. Neurobiol., 95, 579, 10.1016/j.pneurobio.2010.11.005 · DOI
  6. Hansson, 2021, Biomarkers for neurodegenerative diseases, Nat. Med., 27, 954, 10.1038/s41591-021-01382-x · DOI · Paper page
  7. Hampel, 2021, The Amyloid-beta Pathway in Alzheimer's Disease, Mol. Psychiatry, 26, 5481, 10.1038/s41380-021-01249-0 · DOI · Paper page
  8. Ferreira, 2020, Biological subtypes of Alzheimer disease: A systematic review and meta-analysis, Neurology, 94, 436, 10.1212/WNL.0000000000009058 · DOI
  9. Vogel, 2021, Four distinct trajectories of tau deposition identified in Alzheimer's disease, Nat. Med., 27, 871, 10.1038/s41591-021-01309-6 · DOI · Paper page
  10. Jutten, 2021, Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity, Neurology, 96, e2673, 10.1212/WNL.0000000000012022 · DOI
  11. Sims, 2023, Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial, JAMA, 330, 512, 10.1001/jama.2023.13239 · DOI · Paper page
  12. Pang, 2024, Precision medicine analysis of heterogeneity in individual-level treatment response to amyloid beta removal in early Alzheimer's disease, Alzheimers Dement., 20, 1102, 10.1002/alz.13431 · DOI
  13. Mielke, 2022, Performance of plasma phosphorylated tau 181 and 217 in the community, Nat. Med., 28, 1398, 10.1038/s41591-022-01822-2 · DOI · Paper page
  14. Lucey, 2017, Associations Between beta-Amyloid Kinetics and the beta-Amyloid Diurnal Pattern in the Central Nervous System, JAMA Neurol., 74, 207, 10.1001/jamaneurol.2016.4202 · DOI
  15. Lucey, 2017, Diurnal oscillation of CSF Abeta and other AD biomarkers, Mol. Neurodegener., 12, 36, 10.1186/s13024-017-0161-4 · DOI
  16. Dobrowolska, 2014, Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system, PLoS One, 9, e89998, 10.1371/journal.pone.0089998 · DOI
  17. Bateman, 2007, Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker, Neurology, 68, 666, 10.1212/01.wnl.0000256043.50901.e3 · DOI · Paper page
  18. Lucey, 2018, Effect of sleep on overnight cerebrospinal fluid amyloid beta kinetics, Ann. Neurol., 83, 197, 10.1002/ana.25117 · DOI · Paper page
  19. Benedict, 2020, Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men, Neurology, 94, e1181, 10.1212/WNL.0000000000008866 · DOI · Paper page
  20. Brum, 2024, Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals, Alzheimers Dement., 20, 1284, 10.1002/alz.13518 · DOI
  21. Li, 2024, Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset, Ann. Neurol., 95, 951, 10.1002/ana.26891 · DOI
  22. Palmqvist, 2019, Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease, EMBO Mol. Med., 11, e11170, 10.15252/emmm.201911170 · DOI · Paper page
  23. Mila-Aloma, 2022, Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer's disease, Nat Med, 28, 1797
  24. Ashton, 2022, Differential roles of Abeta42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring, Nat. Med., 28, 2555, 10.1038/s41591-022-02074-w · DOI · Paper page
  25. Horie, 2023, CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease, Nat. Med., 29, 1954, 10.1038/s41591-023-02443-z · DOI · Paper page
  26. Salvado, 2023, Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer's disease, medRxiv
  27. Wojdala, 2023, Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP, Neurobiol. Dis., 189, 106356, 10.1016/j.nbd.2023.106356 · DOI · Paper page
  28. Guo, 2023, The dynamics of plasma biomarkers across the Alzheimer's continuum, Alzheimer's Res. Ther., 15, 31, 10.1186/s13195-023-01174-0 · DOI
  29. Fang, 2023, Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients, J. Prev. Alzheimers Dis., 10, 25
  30. Brand, 2022, The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review, Alzheimer's Res. Ther., 14, 195, 10.1186/s13195-022-01117-1 · DOI · Paper page
  31. Hampel, 2023, Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape, Neuron, 111, 2781, 10.1016/j.neuron.2023.05.017 · DOI · Paper page
  32. Budd Haeberlein, 2022, Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease, J. Prev. Alzheimers Dis., 9, 197
  33. Rinne, 2010, 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study, Lancet Neurol., 9, 363, 10.1016/S1474-4422(10)70043-0 · DOI · Paper page
  34. Hansson, 2023, Donanemab in Early Symptomatic Alzheimer’s Disease: Biomarker Results from TRAILBLAZER-ALZ 2. Alzheimer’s Association International Conference, Amsterdam, Netherlands
  35. Sims, 2023, Amyloid Reduction: Donanemab Perspective. Alzheimer’s Association International Conference, Amsterdam, Netherlands
  36. Salloway, 2023, TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease, BJPsych Open, 9, S67, 10.1192/bjo.2023.227 · DOI
  37. Salloway, 2024, TRAILBLAZER-ALZ 4: Directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic alzheimer’s disease - results from 18-months, Alzheimer's & Parkinson's Diseases Conference. Lisbon, Portugal
  38. Bittner, 2022, Gantenerumab treatment increases plasma beta-amyloid(1–42) and decreases plasma pTau, Alzheimer's & Dementia, 18, 10.1002/alz.065684 · DOI
  39. Klein, 2021, Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab, J. Prev. Alzheimers Dis., 8, 3
  40. Voyle, 2018, O1-09-02: The effect of low doses of gantenerumab on amyloid and tau biomarkers in cerebrospinal fluid (csf) in the marguerite road study., Alzheimer’s Dementia, 14, P240, 10.1016/j.jalz.2018.06.2379 · DOI
  41. Salloway, 2021, A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease, Nat. Med., 27, 1187, 10.1038/s41591-021-01369-8 · DOI · Paper page
  42. Bittner, 2023, GRADUATE I and II Results: Effect of Subcutaneous Gantenerumab on Fluid Biomarkers of AD Pathology and Neurodegeneration. Alzheimer's & Parkinson's Diseases Conference, Gothenburg, Sweden
  43. McDade, 2022, Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study, Alzheimer's Res. Ther., 14, 191, 10.1186/s13195-022-01124-2 · DOI
  44. Swanson, 2018, Clinical and biomarker updates from BAN2401 study 201 in early AD. Clinical Trials on Alzheimer’s Disease Congress, Barcelona, Spain
  45. van Dyck, 2023, Lecanemab in Early Alzheimer's Disease, N. Engl. J. Med., 388, 9, 10.1056/NEJMoa2212948 · DOI · Paper page
  46. Irizarry, 2023, Lecanemab: Amyloid Reduction and Evidence of Downstream Biomarker Modification. Alzheimer’s Association International Conference, Amsterdam, Netherlands
  47. Hey, 2024, Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease, Drugs, 84, 811, 10.1007/s40265-024-02067-8 · DOI
  48. Lowe, 2021, Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging, JPAD-J. Prev. Alzheimers Dis., 8, 414
  49. Mintun, 2024, Advances in our understanding of amyloid plaque clearing therapies. Alzheimer’s & Parkinson’s Diseases Conference, Lisbon, Portugal
  50. Spies, 2012, Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer disease, FBL, 17, 2024
  51. Farlow, 2012, Safety and biomarker effects of solanezumab in patients with Alzheimer's disease, Alzheimers Dement., 8, 261, 10.1016/j.jalz.2011.09.224 · DOI
  52. Logovinsky, 2016, Safety and tolerability of BAN2401-a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody, Alzheimer's Res. Ther., 8, 14, 10.1186/s13195-016-0181-2 · DOI
  53. Soderberg, 2023, Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease, Neurotherapeutics, 20, 195, 10.1007/s13311-022-01308-6 · DOI
  54. Barthelemy, 2020, A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease, Nat Med, 26, 398, 10.1038/s41591-020-0781-z · DOI · Paper page
  55. Kaeser, 2022, CSF p-tau increase in response to Abeta-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles, Acta Neuropathol., 143, 287, 10.1007/s00401-021-02400-5 · DOI
  56. Murray, 2022, Global neuropathologic severity of Alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels, Mol. Neurodegener., 17, 85, 10.1186/s13024-022-00578-0 · DOI
  57. Hampel, 2004, Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study, Arch. Gen. Psychiatry, 61, 95, 10.1001/archpsyc.61.1.95 · DOI · Paper page
  58. Bateman, 2022, Phase 2 lecanemab early Alzheimer's Disease study biomarker results and correlations with clinical outcomes, Alzheimer's & Parkinson's Diseases Conference. Barcelona, Spain
  59. Ploia, 2011, JNK plays a key role in tau hyperphosphorylation in Alzheimer's disease models, J. Alzheimers Dis., 26, 315, 10.3233/JAD-2011-110320 · DOI · Paper page
  60. Ashton, 2021, A multicentre validation study of the diagnostic value of plasma neurofilament light, Nat. Commun., 12, 3400, 10.1038/s41467-021-23620-z · DOI · Paper page
  61. Novak, 2021, ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease, Nat. Aging, 1, 521, 10.1038/s43587-021-00070-2 · DOI · Paper page
  62. Khalil, 2020, Serum neurofilament light levels in normal aging and their association with morphologic brain changes, Nat. Commun., 11, 812, 10.1038/s41467-020-14612-6 · DOI · Paper page
  63. Abdelhak, 2022, Blood GFAP as an emerging biomarker in brain and spinal cord disorders, Nat. Rev. Neurol., 18, 158, 10.1038/s41582-021-00616-3 · DOI · Paper page
  64. Kandadi Muralidharan, 2022, Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque-removing agent, in patients with Alzheimer's disease, CPT Pharmacometrics Syst. Pharmacol., 11, 7, 10.1002/psp4.12728 · DOI
  65. Schuck, 2019, Population pharmacokinetic/pharmacodynamic analyses of BAN2401 in patients with early Alzheimer’s disease: correlation of BAN2401 exposure, PET standard uptake value ratio, and cognitive outcomes, Alzheimer’s & Dementia, 15, P1582, 10.1016/j.jalz.2019.09.023 · DOI
  66. Hayato, 2022, Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease, CPT Pharmacometrics Syst. Pharmacol., 11, 1578, 10.1002/psp4.12862 · DOI
  67. Zhu, 2022, Toward Bridging Unmet Medical Need in Early Alzheimer's Disease: An Evaluation of Beta-Amyloid (Abeta) Plaque Burden as a Potential Drug Development Tool, Clin. Pharmacol. Ther., 111, 728, 10.1002/cpt.2536 · DOI
  68. Gueorguieva, 2023, Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease, Alzheimers Dement., 9, e12404
  69. Jack, 2024, Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup, Alzheimers Dement., 10.1002/alz.13859 · DOI · Paper page
  70. Mielke, 2024, Alzheimer disease blood biomarkers: considerations for population-level use, Nat. Rev. Neurol., 20, 495, 10.1038/s41582-024-00989-1 · DOI
  71. Salvado, 2024, Disease staging of Alzheimer's disease using a CSF-based biomarker model, Nat. Aging, 4, 694, 10.1038/s43587-024-00599-y · DOI
  72. Sato, 2024, Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial, Neurol. Ther., 13, 677, 10.1007/s40120-024-00604-x · DOI
  73. Lee, 2022, Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities, Cancers, 14, 4131, 10.3390/cancers14174131 · DOI
  74. Hampel, 2023, The foundation and architecture of precision medicine in neurology and psychiatry, Trends Neurosci., 46, 176, 10.1016/j.tins.2022.12.004 · DOI
  75. Hampel, 2010, Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives, Nat. Rev. Drug Discov., 9, 560, 10.1038/nrd3115 · DOI

Cited by

Sorted by citations

Metadata

Authors
Hu, Y., Cho, M., Sachdev, P., Dage, J., Hendrix, S., Hansson, O., Bateman, R. J., & Hampel, H.
ORCID
Hampel, Harald
Venue
Med
Publisher
Elsevier BV
Published
2024-10
Volume
5
Issue
10
Pages
1206-1226
ISSN
2666-6340
DOI
10.1016/j.medj.2024.08.004
Cited by
42
References
22
Language
en
Licence
Funders
  • Eisai
  • Catholic Medical Center
  • National Institutes of Health (LRAP23, R01 AG077202, U01 AG057195, U24 AG082930, U54 AG065181, MJFF-023365, U01 AG082350, U54 AG054345, U19 AG074879, R01 AG068193, P30 AG072976, R01 AG072474, RD005665, U24 AG021886)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review